The CRISPR Cas patent files, part 2: Is Cpf1/Cas12a a less conflict- prone alternative to Cas9?

CRISPR Cpf1/Cas12a has been discussed as a less conflict prone alternative, patent-wise, to Cas9. This article investigates whether or not this assumption is correct, and comes to the conclusion that the promise that CRISPR Cpf1/Cas12 would make things easier, and be less conflict-prone, is fragile.